BioSpace News Archive

BioLife Solutions , Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the pricing of its public offering of 5,175,000 shares of its common stock at a public offering price of $14.50 per share, before u

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that Executive Directors of the company will present at several r

Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences Company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Bl

Tongji Healthcare Group, Inc. (OTC: TONJ) (the “Company”) is pleased to announce the appointment of new board members and officers, effective as of June 18, 2020.

Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the company’s SARS-CoV-2 RT-PCR test. Prof. Arndt Rolfs, CEO of CENTOGENE, sai

The Blue Cross and Blue Shield of Minnesota Foundation has awarded more than $3.1M in grants to 23 nonprofit organizations in Minnesota. Grant awards are for one or two years and range from $20,000 to $100,000 per year. Eighteen grants are part of the Healthy Start program, which supports efforts to improve access to quality early childhood care and education throughout the state.

inHEART, providing a cloud-based medical image analysis solution for cardiac interventions on patients with arrhythmias, has closed a round of EUR 3.7 million led by Elaia.

Berlin Heart Inc. announced they have completed the Post Approval Surveillance for the EXCOR® Pediatric Ventricular Assist Device, a requirement of the Post Market Approval (PMA) granted by the Food and Drug Administration (FDA), in June 2017

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2020 on Wednesday, July 29, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing 800-263-0877 (in the United States and Canada) or +1 323-794-2094

This unique platform pools thousands of data sources to enable public, patients, and government to end the epidemic.